HIV transmission or death at 6 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth · Breastfeeding infants of HIV‐infected mothers
A once‐daily NVP regimen administered for 6 months showed no clear difference in HIV transmission or death at 6 months among all infants whose HIV… compared with a once‐daily NVP regimen administered (low certainty).
1 finding from 1 review
HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in HIV transmission at 28 weeks among those whose diagnostic testing… compared with an extended NVP regimen administered to infants (moderate certainty).
1 finding from 1 review
Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infant mortality at 28 weeks among those whose diagnostic testing… compared with an extended NVP regimen administered to infants (moderate certainty).
1 finding from 1 review
HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks · HIV‐infected mothers and their breastfeeding infants
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in HIV transmission or death at 28 weeks among those whose diagnostic… compared with an extended NVP regimen administered to infants (moderate certainty).
1 finding from 1 review
Infants with Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infants with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
1 finding from 1 review
Mothers with Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
An extended antiretroviral regimen administered to mothers for 28… may leads to higher mothers with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
1 finding from 1 review
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP regimen administered to infants for 14 weeks changes infants with Probably Related Severe Adverse Events11 compared with sdNVP plus ZDV (1week) (very low certainty).
1 finding from 1 review
HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers
An extended NVP plus ZDV regimen administered to infants for 14 weeks probably leads to lower HIV Transmission at 9 months among those whose HIV diagnostic… compared with sdNVP plus ZDV (1 week) (moderate certainty).
1 finding from 1 review
Energy intake · patients with reducing morbidity and mortality in people with HIV
1 finding from 1 review
Protein intake (g/day) · patients with reducing morbidity and mortality in people with HIV
1 finding from 1 review
Weight (kg) · patients with reducing morbidity and mortality in people with HIV
1 finding from 1 review
Fat mass measured in % of TBW · patients with reducing morbidity and mortality in people with HIV
1 finding from 1 review
Fat free mass · patients with reducing morbidity and mortality in people with HIV
1 finding from 1 review
CD4 cell count · patients with reducing morbidity and mortality in people with HIV
1 finding from 1 review
Viral load · patients with reducing morbidity and mortality in people with HIV
1 finding from 1 review
Virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+ weeks after randomisation · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+… compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
Virologic suppression Viral load < 50 copies/ml · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic suppression Viral load < 50 copies/ml compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
CD4 cell count · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
1 finding from 1 review
Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in severe adverse events compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
Hypersensitivity · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in hypersensitivity reactions compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review